Ras signaling in prostate cancer progression

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 13-25

  Weber, Michael J ^a,b   Gioeli, Daniel ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Androgen receptor; MAP kinase; Signal transduction

Indexed keywords

ANDROGEN; GROWTH FACTOR; RAS PROTEIN; RECEPTOR; ANDROGEN RECEPTOR;

CANCER GROWTH; HUMAN; HYPERSENSITIVITY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; MALE; METABOLISM; NEOPLASM; PHYSIOLOGY; PROSTATE TUMOR;

ANDROGENS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RAS PROTEINS; RECEPTORS, ANDROGEN;

EID: 3242756036     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10683     Document Type: Review

References (105)

1. Aarnisalo P, Palvimo JJ, Janne OA. 1998. CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95:2122-2127.
2. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. 1999. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19:5143-5154.
3. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. 2003a. Attenuation of endogenous Ras signaling restores androgen sensitivity to hormone refactory C4-2 prostate cancer cells. Cancer Res
4. Bakin RE, Gioeli D, Sikes RA, Weber MJ. 2003b. Constitutive activation of the Ras/MAP kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate epithelial cells. Cancer Res
5. Bar-Sagi D. 2001. A Ras by any other name. Mol Cell Biol 21:1441-1443.
6. Berger SL. 2002. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12:142-148.
7. Berthiaume LG. 2002. Insider information: How palmitoylation of Ras makes it a signaling double agent. Sci STKE E41.
8. Bos JL. 1989. Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689.
9. Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L. 1996. c-Jun can mediate androgen receptor-induced transactivation. J Biol Chem 271:24583-24589.
10. Bubulya A, Zhou XF, Shen XQ, Fisher CJ, Shemshedini L. 2000. c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine 13:55-62.
11. Bubulya A, Chen SY, Fisher CJ, Zheng Z, Shen XQ, Shemshedini L. 2001. c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. J Biol Chem 276:44704-44711.
12. Carson JP, Kulik G, Weber MJ. 1999. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 59:1449-1453.
13. Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA, Davie JE. 1999. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 274:24914-24920.
14. Chen CD, Sawyers CL. 2002. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-2870.
15. Chen T, Cho RW, Stork PJ, Weber MJ. 1999. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59: 213-218.
16. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859.
17. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. 2001. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J 20: 3484-3494.
18. Coker KJ, Staros JV, Guyer CA. 1994. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. Proc Natl Acad Sci USA 91:6967-6971.
19. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. 2003. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162:233-241.
20. Craft N, Sawyers CL. 1998. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metast Rev 17:421-427.
21. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. 1999a. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59:5030-5036.
22. Craft N, Shostak Y, Carey M, Sawyers CL. 1999b. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
23. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
24. Culig Z, Hobisch A, Bartsch G, Klocker H. 2000. Androgen receptor-An update of mechanisms of action in prostate cancer. Urological Res 28:211-219.
25. Culig Z, Bartsch G, Hobisch A. 2002a. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 197:231-238.
26. Culig Z, Klocker H, Bartsch G, Hobisch A. 2002b. Androgen receptors in prostate cancer. Endocr Relat Cancer 9:155-170.
27. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM. 2002. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 8:2399-2405.
28. Dancey JE, Freidlin B. 2003. Targeting epidermal growth factor receptor-Are we missing the mark? Lancet 362:62-64.
29. Darne C, Veyssiere G, Jean C. 1998. Phorbol ester causes ligand-independent activation of the androgen receptor. Eur J Biochem 256:541-549.
30. de Ruiter PE, Teuwen R, Trapman J, Dijkema R, Brinkmann AO. 1995. Synergism between androgens and protein kinase-C on androgen-regulated gene expression. Mol Cell Endocrinol 110:R1-R6.
31. Debes JD, Tindall DJ. 2002. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 187:1-7.
32. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
33. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AS, Ciardiello F. 2002. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438-3444.
34. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. 1997. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052-1064.
35. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H. 2002. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9:117-125.
36. Ehrhardt A, Ehrhardt GR, Guo X, Schrader JW. 2002. Ras and relatives-Job sharing and networking keep an old family together. Exp Hematol 30:1089-1106.
37. Featherstone M. 2002. Coactivators in transcription initiation: Here are your orders. Curr Opin Genet Dev 12:149-155.
38. Feig LA, Buchsbaum RJ. 2002. Cell signaling: Life or death decisions of ras proteins. Curr Biol 12:R259-R261.
39. Font dM, Brown M. 2000. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041-5047.
40. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. 1998. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273:31853-31859.
41. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Janne OA, Pestell RG. 2002. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22:3373-3388.
42. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. 2002. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277:25904-25913.
43. Geiman TM, Robertson KD. 2002. Chromatin remodeling, histone modifications, and DNA methylation-How does it all fit together? J Cell Biochem 87:117-125.
44. Gelmann EP. 2002. Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015.
45. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. 1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284.
46. Gioeli D, Zecevic M, Weber MJ. 2001. Immunostaining for activated extracellular signal-regulated kinases in cells and tissues. Methods Enzymol 332:343-353.
47. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304-29314.
48. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. 2001. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928-1936.
49. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577.
50. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724.
51. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001a. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
52. Gregory CW, Johnson RT, Jr. Mohler JL, French FS, Wilson EM. 2001b. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898.
53. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
54. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM. 2002. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045-2057.
55. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: An overview. Endocrine Rev 23:175-200.
56. Huang H, Tindall DJ. 2002. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr 12:193-207.
57. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA. 1994. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 135:1359-1366.
58. Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, Scita G. 2002. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol 156:125-136.
59. Isaacs W, De Marzo A, Nelson WG. 2002. Focus on prostate cancer. Cancer Cell 2:113-116.
60. Jenster G, de Ruiter PE, van der Korput HA, Kuiper GG, Trapman J, Brinkmann AO. 1994. Changes in the abundance of androgen receptor isotypes: Effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33:14064-14072.
61. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002a. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 22:5222-5234.
62. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002b. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283-30288.
63. Langley E, Zhou ZX, Wilson EM. 1995. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990.
64. Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68:1-9.
65. Lin HK, Yeh S, Kang HY, Chang C. 2001. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205.
66. Lowy DR, Willumsen BM. 1993. Function and regulation of ras. Ann Rev Biochem 62:851-891.
67. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM. 1988a. The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2:1265-1275.
68. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. 1988b. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327-330.
69. McKenna NJ, O'Malley BW. 2002a. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474.
70. McKenna NJ, O'Malley BW. 2002b. Minireview: Nuclear receptor coactivators-An update. Endocrinology 143: 2461-2465.
71. Mellinghoff IK, Tran C, Sawyers CL. 2002. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62:5254-5259.
72. Nazareth LV, Weigel NL. 1996. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907.
73. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H. 2000. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 45:124-131.
74. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. 2001. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276-6280.
75. Poukka H, Karvonen U, Janne OA, Palvimo JJ. 2000. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150.
76. Reinikainen P, Palvimo JJ, Janne OA. 1996. Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137:4351-4357.
77. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG. 2001. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/ CAF)-dependent manner. Mol Endocrinol 15:797-811.
78. Rowan BG, Garrison N, Weigel NL, O'Malley BW. 2000a. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 20:8720-8730.
79. Rowan BG, Weigel NL, O'Malley BW. 2000b. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475-4483.
80. Sadar MD. 1999. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783.
81. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. 1995. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550.
82. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, Mahadevan LC, Arthur JS. 2003. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 22:2788-2797.
83. Stallcup MR. 2001. Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20:3014-3020.
84. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z. 2003. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162:655-663.
85. Stork PJ, Schmitt JM. 2002. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258-266.
86. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. 2000. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 44:91-103.
87. Tillman K, Oberfield JL, Shen XQ, Bubulya A, Shernshedini L. 1998. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine 9:193-200.
88. Voeller HJ, Wilding G, Gelmann EP. 1991. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol Endocrinol 5:209-216.
89. Walsh AB, Bar-Sagi D. 2001. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 276:15609-15615.
90. Wang Q, Lu J, Yong EL. 2001. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 276:7493-7499.
91. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. 2001. Signal pathways which promote invasion and metastasis: Critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 21:5958-5969.
92. Weigel NL. 1996. Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657-667.
93. Weigel NL, Zhang Y. 1998. Ligand-independent activation of steroid hormone receptors. J Mol Med 76:469-479.
94. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L. 2002. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8:979-986.
95. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
96. Weston CR, Davis RJ. 2002. The JNK signal transduction pathway. Curr Opin Genet Dev 12:14-21.
97. Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ, Shemshedini L. 1998. Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 18:2001-2009.
98. Wright JD, Reuter CW, Weber MJ. 1995. An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors. J Biol Chem 270:12085-12093.
99. Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW. 2002. Regulation of SRC-3 (pCIP/ ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase. Mol Cell Biol 22:3549-3561.
100. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. 1998. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-1925.
101. Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C. 1999. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11:195-202.
102. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. 2000. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275:40846-40855.
103. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
104. Zhou ZX, Kemppainen JA, Wilson EM. 1995. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605-615.
105. Zhu Z, Bulgakov OV, Scott SS, Dalton JT. 2001. Recombinant expression and purification of human androgen receptor in a baculovirus system. Biochem Biophys Res Commun 284:828-835.